Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Get Free Report) COO Tina Marriott sold 6,000 shares of the firm’s stock in a transaction dated Thursday, September 26th. The stock was sold at an average price of $7.00, for a total transaction of $42,000.00. Following the transaction, the chief operating officer now owns 521,138 shares of the company’s stock, valued at approximately $3,647,966. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.
Tina Marriott also recently made the following trade(s):
- On Thursday, August 29th, Tina Marriott sold 6,000 shares of Recursion Pharmaceuticals stock. The stock was sold at an average price of $7.56, for a total transaction of $45,360.00.
- On Thursday, July 25th, Tina Marriott sold 6,000 shares of Recursion Pharmaceuticals stock. The stock was sold at an average price of $8.13, for a total transaction of $48,780.00.
Recursion Pharmaceuticals Stock Down 5.6 %
NASDAQ:RXRX opened at $6.59 on Tuesday. The stock’s fifty day moving average price is $7.00 and its two-hundred day moving average price is $8.16. Recursion Pharmaceuticals, Inc. has a 52-week low of $4.97 and a 52-week high of $15.74. The company has a debt-to-equity ratio of 0.04, a quick ratio of 6.07 and a current ratio of 6.07. The company has a market cap of $1.57 billion, a price-to-earnings ratio of -4.12 and a beta of 0.82.
Analysts Set New Price Targets
A number of research analysts have recently issued reports on RXRX shares. Jefferies Financial Group cut their target price on shares of Recursion Pharmaceuticals from $8.00 to $6.00 and set a “hold” rating for the company in a research note on Tuesday, September 3rd. KeyCorp cut their target price on shares of Recursion Pharmaceuticals from $16.00 to $12.00 and set an “overweight” rating for the company in a research note on Thursday, July 11th. Needham & Company LLC cut their target price on shares of Recursion Pharmaceuticals from $16.00 to $11.00 and set a “buy” rating for the company in a research note on Wednesday, September 4th. Finally, Leerink Partners cut their target price on shares of Recursion Pharmaceuticals from $9.00 to $8.00 and set a “market perform” rating for the company in a research note on Tuesday, September 3rd. Four investment analysts have rated the stock with a hold rating and two have given a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $9.40.
Get Our Latest Analysis on Recursion Pharmaceuticals
Institutional Inflows and Outflows
Several large investors have recently bought and sold shares of RXRX. Dimensional Fund Advisors LP lifted its holdings in Recursion Pharmaceuticals by 152.9% during the 4th quarter. Dimensional Fund Advisors LP now owns 2,137,110 shares of the company’s stock worth $21,079,000 after buying an additional 1,291,946 shares in the last quarter. UBS Group AG raised its position in shares of Recursion Pharmaceuticals by 101.9% during the 4th quarter. UBS Group AG now owns 691,911 shares of the company’s stock valued at $6,822,000 after acquiring an additional 349,232 shares during the last quarter. Nomura Asset Management Co. Ltd. bought a new stake in shares of Recursion Pharmaceuticals during the 4th quarter valued at $457,000. Lingotto Investment Management LLP raised its position in shares of Recursion Pharmaceuticals by 141.9% during the 4th quarter. Lingotto Investment Management LLP now owns 1,875,077 shares of the company’s stock valued at $18,488,000 after acquiring an additional 1,100,000 shares during the last quarter. Finally, CIBC Private Wealth Group LLC bought a new stake in shares of Recursion Pharmaceuticals during the 4th quarter valued at $1,348,000. Institutional investors and hedge funds own 89.06% of the company’s stock.
Recursion Pharmaceuticals Company Profile
Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.
Featured Articles
- Five stocks we like better than Recursion Pharmaceuticals
- What is the Nikkei 225 index?
- TJX Stock: A Buying Opportunity Before the Holiday Rush
- What Are Dividend Challengers?
- Micron’s Blowout Results Pave the Way for Seagate’s Stock Surge
- Insider Trading – What You Need to Know
- Zeta Global’s AI Cloud: Your Secret Weapon for Massive Growth
Receive News & Ratings for Recursion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recursion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.